Craig D Logsdon

Title: Inventor Spotlight: Craig D. Logsdon

Introduction

Craig D. Logsdon is a prolific inventor based in Houston, Texas, recognized for his significant contributions to the field of medical treatments, particularly in cancer therapy. With a total of four patents to his name, Logsdon continues to advance innovative solutions through his research and development efforts.

Latest Patents

Among his latest patents, Logsdon has developed blocking monoclonal antibodies to AGR2 and its receptor C4.4A. These antibodies are designed to recognize and block interactions of other molecules with AGR2 and C4.4A, offering potential methods for treating cancer. His other notable patent includes compositions and methods for utilizing cathepsin E cleavable substrates, which consist of therapeutic agents linked to substrates capable of being cleaved by cathepsin E. This invention provides methods for treating symptoms related to diseases characterized by expression of cathepsin E, including the elimination of cancer cells expressing this molecule.

Career Highlights

Craig D. Logsdon has had a distinguished career, earning valuable experience through positions at prominent institutions, including the University of Texas System and The Methodist Hospital System. His work in these organizations has allowed him to apply his inventive skills to pressing medical challenges.

Collaborations

During his career, Logsdon has collaborated with talented individuals, including Ching-Hsuan Tung and Zobeida Cruz-Monserrate. These collaborations have contributed to the enhancement of research quality and the effectiveness of new inventions in the medical domain.

Conclusion

Craig D. Logsdon's innovative work in developing monoclonal antibodies and therapeutic agents illustrates his commitment to advancing cancer treatment options. His patents demonstrate a fusion of creativity and scientific rigor that holds the promise of improved health outcomes for patients facing complex medical conditions.